Monitoring anticoagulation and hemostasis in cardiac surgery

Anesthesiology Clinics of North America

Volumn 21, Issue 3, 2003, Pages 511-526

  Shore Lesserson, Linda ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGATROBAN; HEPARIN; HIRUDIN; HIRULOG; PROTAMINE; THROMBIN INHIBITOR;

ANTICOAGULATION; BLOOD CLOTTING; BLOOD CLOTTING TEST; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; DEVICE; DRUG BLOOD LEVEL; DRUG MONITORING; HEART SURGERY; HEMATOLOGIC DISEASE; HEMOSTASIS; HUMAN; MONITOR; PATIENT MONITORING; POSTOPERATIVE PERIOD; REVIEW; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA;

EID: 0141453795     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8537(03)00036-1     Document Type: Review

References (64)

1. Hirsh J. Heparin. N Engl J Med 1991;324:1565-74.
2. Despotis GJ, Joist JH. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update. J Cardiothorac Vasc Anesth 1999;13(Suppl 1): 18-29; discussion 36-7.
3. Niles SD, Sutton RG, Ploessl J, et al. Correlation of ACT as measured with three commercially available devices with circulating heparin level during cardiac surgery. J Extra Corpor Technol 1995;27:197-200.
4. Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994;108:1076-82.
5. Reich DL, Zahl K, Perucho MH, et al. An evaluation of two activated clotting time monitors during cardiac surgery. J Clin Monit 1992;8:33-6.
6. Horkay F, Martin P, Rajah SM, et al. Response to heparinization in adults and children undergoing cardiac operations. Ann Thorac Surg 1992;53:822-6.
7. Despotis GJ, Summerfield AL, Joist JH, et al. In vitro reversal of heparin effect with heparinase: evaluation with whole blood prothrombin time and activated partial thromboplastin time in cardiac surgical patients. Anesth Analg 1994;79:670-4.
8. Tuman KJ, McCarthy RJ, Djuric M, et al. Evaluation of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelastographic assay. J Cardiothorac Vasc Anesth 1994;8:144-9.
9. Babka R, Colby C, El-Etr A, et al. Monitoring of intraoperative heparinization and blood loss following cardiopulmonary bypass surgery. J Thorac Cardiovasc Surg 1977;73:780-2.
10. Despotis GJ, Joist JH, Hogue Jr. CW, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996;76:902-8.
11. Culliford AT, Gitel SN, Starr N, et al. Lack of correlation between activated clotting time and plasma heparin during cardiopulmonary bypass. Ann Surg 1981;193:105-11.
12. Ammar T, Fisher CF, Sarier K, et al. The effects of thrombocytopenia on the activated coagulation time. Anesth Analg 1996;83:1185-8.
13. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997;95:614-7.
14. Bode AP, Lust RM. Masking of heparin activity in the activated coagulation time (ACT) by platelet procoagulant activity. Thromb Res 1994;73:285-300.
15. Gravlee GP, Whitaker CL, Mark LJ, et al. Baseline activated coagulation time should be measured after surgical incision. Anesth Analg 1990;71:549-53.
16. Andrew M, MacIntyre B, MacMillan J, et al. Heparin therapy during cardiopulmonary bypass in children requires ongoing quality control. Thromb Haemost 1993;70:937-41.
17. Young JA, Kisker CT, Doty DB. Adequate anticoagulation during cardiopulmonary bypass determined by activated clotting time and the appearance of fibrin monomer. Ann Thorac Surg 1978;26:231-40.
18. Metz S, Keats AS. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding. Ann Thorac Surg 1990;49:440-4.
19. Cardoso PF, Yamazaki F, Keshavjee S, et al. A reevaluation of heparin requirements for cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;101:153-60.
20. Young E, Prins M, Levine MN, et al. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992;67:639-43.
21. Levy JH, Montes F, Szlam F, et al. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. Anesth Analg 2000;90:1076-9.
22. Levy JH, Despotis GJ, Szlam F, et al. Recombinant human transgenic antithrombin in cardiac surgery: A dose-finding study. Anesthesiology 2002;96:1095-102.
23. Nicholson SC, Keeling DM, Sinclair ME, et al. Heparin pretreatment does not alter heparin requirements during cardiopulmonary bypass. Br J Anaesth 2001;87:844-7.
24. Shore-Lesserson L, Manspeizer HE, Bolastig M, et al. Anticoagulation for cardiac surgery in patients receiving preoperative heparin: use of the high-dose thrombin time. Anesth Analg 2000;90:813-8.
25. Esposito RA, Culliford AT, Colvin SB, et al. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment. J Thorac Cardiovasc Surg 1983;85:346-53.
26. Bull BS, Huse WM, Brauer FS, et al. Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975;69:685-9.
27. Bull MH, Huse WM, Bull BS. Evaluation of tests used to monitor heparin therapy during extracorporeal circulation. Anesthesiology 1975;43:346-53.
28. Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 1995;110:36-45.
29. Shore-Lesserson L, Reich DL, DePerio M. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. Can J Anaesth 1998;45:10-8.
30. Shigeta O, Kojima H, Hiramatsu Y, et al. Low-dose protamine based on heparin-protamine titration method reduces platelet dysfunction after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1999;118:354-60.
31. Gravlee GP, Haddon WS, Rothberger HK, et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. J Thorac Cardiovasc Surg 1990;99:518-27.
32. Despotis GJ, Joist JH, Hogue Jr. CW, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995;110:46-54.
33. Wang JS, Lin CY, Karp RB. Comparison of high-dose thrombin time with activated clotting time for monitoring of anticoagulant effects of heparin in cardiac surgical patients. Anesth Analg 1994;79:9-13.
34. Wang JS, Lin CY, Hung WT, et al. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin. Anesthesiology 1992;77:1080-4.
35. Dietrich W, Dilthey G, Spannagl M, et al. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study. Anesthesiology 1995;83:679-89; discussion 29A-30.
36. Tabuchi N, Njo TL, Tigchelaar I, et al. Monitoring of anticoagulation in aprotinin-treated patients during heart operation. Ann Thorac Surg 1994;58:774-7.
37. Fitch JC, Geary KL, Mirto GP, et al. Heparin management test versus activated coagulation time during cardiovascular surgery: Correlation with anti-Xa activity. J Cardiothorac Vasc Anesth 1999;13:53-7.
38. Gibbs NM, Weightman WM, Thackray NM, et al. Evaluation of the TAS coagulation analyzer for monitoring heparin effect in cardiac surgical patients. J Cardiothorac Vasc Anesth 1998;12:536-41.
39. Koster A, Kuppe H, Crystal GJ, et al. Cardiovascular surgery without cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II using anticoagulation with recombinant hirudin. Anesth Analg 2000;90:292-8.
40. Koster A, Meyer O, Hetzer R, et al. Some new perspectives in heparin-induced thrombocytopenia type II. J Extra Corpor Technol 2001;33:193-6.
41. Koster A, Hansen R, Grauhan O, et al. Hirudin monitoring using the TAS ecarin clotting time in patients with heparin-induced thrombocytopenia type II. J Cardiothorac Vasc Anesth 2000;14:249-52.
42. Koster A, Loebe M, Hansen R, et al. A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: Adaptation of the ecarin clotting time to the act II device. J Thorac Cardiovasc Surg 2000;119:1278-83.
43. Gravlee GP, Rogers AT, Dudas LM, et al. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology 1992;76:393-401.
44. Despotis GJ, Grishaber JE, Goodnough LT. The effect of an intraoperative treatment algorithm on physicians' transfusion practice in cardiac surgery. Transfusion 1994;34:290-6.
45. Nuttall GA, Oliver WC, Santrach PJ, et al. Efficacy of a simple intraoperative transfusion algorithm for nonerythrocyte component utilization after cardiopulmonary bypass. Anesthesiology 2001;94:773-81; discussion 5A-6.
46. Shore-Lesserson L, Manspeizer HE, DePerio M, et al. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999;88:312-9.
47. Reich DL, Yanakakis MJ, Vela-Cantos FP, et al. Comparison of bedside coagulation monitoring tests with standard laboratory tests in patients after cardiac surgery. Anesth Analg 1993;77:673-9.
48. Samama CM, Quezada R, Riou B, et al. Intraoperative measurement of activated partial thromboplastin time and prothrombin time with a new compact monitor. Acta Anaesthesiol Scand 1994;38:232-7.
49. Werner M, Gallagher JV, Ballo MS, et al. Effect of analytic uncertainty of conventional and point-of-care assays of activated partial thromboplastin time on clinical decisions in heparin therapy. Am J Clin Pathol 1994;102:237-41.
50. Nuttall GA, Oliver WC, Beynen FM, et al. Determination of normal versus abnormal activated partial thromboplastin time and prothrombin time after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1995;9:355-61.
51. Burns ER, Billett HH, Frater RW, et al. The preoperative bleeding time as a predictor of postoperative hemorrhage after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1986;92:310-2.
52. Burns ER, Lawrence C. Bleeding time. A guide to its diagnostic and clinical utility. Arch Pathol Lab Med 1989;113:1219-24.
53. Spiess BD, Gillies BS, Chandler W, et al. Changes in transfusion therapy and reexploration rate after institution of a blood management program in cardiac surgical patients. J Cardiothorac Vasc Anesth 1995;9:168-73.
54. Hett DA, Walker D, Pilkington SN, et al. Sonoclot analysis. Br J Anaesth 1995;75:771-6.
55. Nuttall GA, Oliver WC, Ereth MH, et al. Coagulation tests predict bleeding after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997;11:815-23.
56. Stern MP, DeVos-Doyle K, Viguera MG, et al. Evaluation of post-cardiopulmonary bypass Sonoclot signatures in patients taking nonsteroidal anti-inflammatory drugs. J Cardiothorac Anesth 1989;3:730-3.
57. Tuman KJ, Spiess BD, McCarthy RJ, et al. Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass. Anesth Analg 1989;69:69-75.
58. Despotis GJ, Levine V, Saleem R, et al. Use of point-of-care test in identification of patients who can benefit from desmopressin during cardiac surgery: A randomised controlled trial. Lancet 1999;354:106-10.
59. Lakkis N, Lakiss N, Bobek J, et al. Platelet inhibition with tirofiban early during percutaneous coronary intervention: Dosing revisited. Catheter Cardiovasc Interv 2002;56:474-7.
60. Smith JW, Steinhubl SR, Lincoff AM, et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 1999;99:620-5.
61. Bock M, De Haan J, Beck KH, et al. Standardization of the PFA-100(R) platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives. Br J Haematol 1999;106:898-904.
62. Slaughter TF, Sreeram G, Sharma AD, et al. Reversible shear-mediated platelet dysfunction during cardiac surgery as assessed by the PFA-100 platelet function analyzer. Blood Coagul Fibrinolysis 2001;12:85-93.
63. Griffin MJ, Rinder HM, Smith BR, et al. The effects of heparin, protamine, and heparin/protamine reversal on platelet function under conditions of arterial shear stress. Anesth Analg 2001;93:20-7.
64. Faraday N, Guallar E, Sera VA, et al. Utility of whole blood hemostatometry using the clot signature analyzer for assessment of hemostasis in cardiac surgery. Anesthesiology 2002;96:1115-22.